Sperry et al. demonstrated that U87 glioma cell lines as well as cell culture lines derived from GBM patients, including those with mutations in the mTOR/AKT/PI3K/IDH1 signaling pathways, can use KBs for tumor growth under standard and physiological culture conditions. This evidence concerns the gene MTOR and central nervous system cancer.